Search results for "Blood"

showing 10 items of 5199 documents

Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension

1997

OBJECTIVE To analyze the relationship between insulinemia and urinary albumin excretion in a group of nonobese, young adult hypertensive patients, who had never been treated with antihypertensive drugs. PATIENTS AND METHODS Forty-nine patients who fulfilled the inclusion criteria were included. Twenty-four-hour ambulatory blood pressure monitorings, urinary albumin excretion (UAE) measurements, and an oral glucose-tolerance test measuring glucose and insulin, were performed, and left ventricular mass was measured by echocardiography. Hypertensive patients were classified as normoalbuminuric when their UAE was < 30 mg/24 h (40 patients; mean UAE 13.4 +/- 7.0 mg/24 h), and as microalbuminuric…

AdultBlood GlucoseMalemedicine.medical_specialtyAmbulatory blood pressurePhysiologymedicine.medical_treatmentUrologyBlood PressureEssential hypertensionRisk FactorsHyperinsulinismInternal medicineInternal MedicineHyperinsulinemiamedicineAlbuminuriaHumansInsulinProteinuriabusiness.industryInsulinArea under the curveGlucose Tolerance TestMiddle Agedmedicine.diseaseBlood pressureEndocrinologyCardiovascular DiseasesCase-Control StudiesHypertensionFemaleMicroalbuminuriamedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersJournal of Hypertension
researchProduct

Are general practitioners characteristics associated with the quality of type 2 diabetes care in general practice? Results from the Norwegian ROSA4 s…

2018

Abstract Objective: To explore the associations between general practitioners (GPs) characteristics such as gender, specialist status, country of birth and country of graduation and the quality of care for patients with type 2 diabetes (T2DM). Design: Cross-sectional survey. Setting and subjects: The 277 GPs provided care for 10082 patients with T2DM in Norway in 2014. The GPs characteristics were self-reported: 55% were male, 68% were specialists in General Practice, 82% born in Norway and 87% had graduated in Western Europe. Of patients, 81% were born in Norway and 8% in South Asia. Data regarding diabetes care were obtained from electronic medical records and manually verified. Main outc…

AdultBlood GlucoseMalemedicine.medical_specialtyAsiaCross-sectional studyGeneral PracticeEthnic groupBlood PressureNorwegian030204 cardiovascular system & hematology03 medical and health sciencesspecializationfamily medicine0302 clinical medicineGeneral Practitionersquality of careEthnicitymedicinegenderHumans030212 general & internal medicinePractice Patterns Physicians'Screening proceduresQuality of Health CareGlycated HemoglobinNorwaybusiness.industrylcsh:Public aspects of medicineMedical recordPublic Health Environmental and Occupational Healthlcsh:RA1-1270Type 2 diabetesMiddle Agedlanguage.human_languagePeer reviewEuropeCross-Sectional StudiesDiabetes Mellitus Type 2Family medicinegeneral practitionerlanguageGlobal Positioning SystemFemaleGuideline AdherencebusinessResearch ArticleGraduation
researchProduct

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin lev…

2013

OBJECTIVE: Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly diagnosed prolactinoma in relation to disease control and CAB dosage. DESIGN: This is a retrospective clinical-based therapy analysis. PATIENTS: Forty-three patients with prolactinoma (eight men, 35 women), aged 33·65 ± 11·23 years, were evaluated metabolically at baseline and after 12 months of CAB treatment. MEASUREMENTS: Body mass index (BMI), systolic and diastolic blood pressure, waist circumference (WC), lipid profile, haemoglobinA1c (…

AdultBlood GlucoseMalemedicine.medical_specialtyCabergolineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPituitary neoplasmSettore MED/13 - EndocrinologiaBody Mass IndexYoung AdultEndocrinologyInsulin resistanceInternal medicineCabergolineMedicineHumansPituitary NeoplasmsProlactinomaErgolinesProlactinomaAdiposityRetrospective Studiesmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryInsulinmedicine.diseaseLipidsProlactinBlood pressureEndocrinologyDopamine AgonistsMetabolomeFemaleInsulin ResistanceWaist CircumferencebusinessLipid profileBody mass indexmedicine.drugClinical endocrinology
researchProduct

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2…

2019

Norursodeoxycholic acid is an orally administered side chain-shortened homologue of ursodeoxycholic acid that undergoes hepatic enrichment with hepatoprotective, anti-inflammatory, and antifibrotic activity. We assessed the efficacy of two doses of norursodeoxycholic acid versus placebo for the treatment of non-alcoholic fatty liver disease.We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 dose-finding clinical trial in tertiary referral hospitals and medical centres in Austria (n=6) and Germany (n=23) for patients with non-alcoholic fatty liver disease with or without diabetes. Patients with a clinical diagnosis of non-alcoholic fatty liver disease and serum alani…

AdultBlood GlucoseMalemedicine.medical_specialtyCholagogues and CholereticsPopulationPlaceboGastroenterologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawNon-alcoholic Fatty Liver DiseaseDiabetes mellitusInternal medicinemedicineHumansAspartate Aminotransferaseseducationeducation.field_of_studyHepatologyDose-Response Relationship Drugbusiness.industryFatty liverUrsodeoxycholic AcidGastroenterologyAlanine TransaminaseMiddle Agedmedicine.diseaseLipidsUrsodeoxycholic acidClinical trialDose–response relationshipTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemalebusinessmedicine.drugThe lancet. Gastroenterologyhepatology
researchProduct

Effects of muscular exercise on erythrocyte adenosine triphosphate concentration in patients with insulin-dependent diabetes mellitus.

1987

Type I diabetes mellitus represents a metabolic disorder in which intracellular glycolytic pathway is inhibited by insulin deficiency, with the subsequent decreased availability of energetic substrates such as ATP. Some aspects of the energetic metabolism in response to an intensive demand (muscular exercise) were investigated, in a group of 10 ketotic diabetic patients, by measuring erythrocyte adenosine triphosphate (ATP) and blood glucose, free fatty acids (FFA) and lactate levels. In the diabetic subjects, in comparison with normal subjects, the decreased levels of erythrocyte ATP at rest did not increase after exercise, while the increased levels of FFA at rest did not diminish after e…

AdultBlood GlucoseMalemedicine.medical_specialtyContraction (grammar)ErythrocytesClinical BiochemistryPhysical ExertionFatty Acids NonesterifiedDiabetic Ketoacidosischemistry.chemical_compoundAdenosine TriphosphateInternal medicinemedicineHumansGlycolysisIn patientHematologyChemistryMusclesMetabolic disorderMetabolismmedicine.diseaseEndocrinologyDiabetes Mellitus Type 1LactatesFemaleEnergy MetabolismAdenosine triphosphateIntracellularLa Ricerca in clinica e in laboratorio
researchProduct

Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide

2018

Purpose: To evaluate the effect of pasireotide on β-cell and adipose function in patients with Cushing’s disease (CD). Methods: Clinical and hormonal parameters, insulin secretion evaluated by HOMA-β and by the area under the curve (AUC2h) of C-peptide during a mixed meal tolerance test and insulin sensitivity, evaluated by the euglycaemic hyperinsulinaemic clamp, were evaluated in 12 patients with active CD, before and after 6 and 12 months of pasireotide. In addition, a panel of adipokines including leptin (Ob), leptin/leptin receptor ratio (Ob/Ob-R ratio), adiponectin, resistin, visfatin, adipocyte fatty acid binding protein (AFABP) and non-esterified fatty acids (NEFAs) was evaluated at…

AdultBlood GlucoseMalemedicine.medical_specialtyDiabetes mellituInjections SubcutaneousEndocrinology Diabetes and MetabolismAdipose tissueAdipokine030209 endocrinology & metabolism030204 cardiovascular system & hematologySettore MED/13 - EndocrinologiaCohort StudiesYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyAdipokinesInternal medicineDiabetes mellitusAdipokinemedicineHumansInsulinPituitary ACTH HypersecretionLeptin receptorAdiponectinbusiness.industryLeptinBody WeightMiddle AgedCushing’s diseasemedicine.diseaseInsulin sensitivityHormonesPasireotidePasireotideTreatment OutcomeEndocrinologychemistryFemaleResistinInsulin ResistanceSomatostatinbusiness
researchProduct

Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population.

2004

We investigated the association of C1431T and Pro12Ala polymorphisms at the peroxisome proliferator-activated receptor γ (PPARγ) locus with plasma lipids and insulin resistance-related variables, according to diabetes status, in a large and representative Asian population from Singapore consisting of 2,730 Chinese, 740 Malays, and 568 Indians. Moreover, we estimated the diabetes risk and examined gene-nutrient interactions between these variants and the ratio of polyunsaturated fatty acid to saturated fat (SFA) in determining body mass index (BMI) and fasting insulin. We found differential effects of these gene variants. The Pro12Ala polymorphism was more associated with plasma lipids and f…

AdultBlood GlucoseMalemedicine.medical_specialtyDiabetes riskAsiaSaturated fatmedicine.medical_treatmentMutation MissensePeroxisome proliferator-activated receptorLocus (genetics)QD415-436BiologyBiochemistryPolymorphism Single NucleotidepolymorphismBody Mass IndexEndocrinologyRisk FactorsfatDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansInsulinAllelechemistry.chemical_classificationperoxisome proliferator-activated receptorInsulinFatty AcidsCell BiologyMiddle Agedmedicine.diseaseLipidsPPAR gammaEndocrinologychemistryFatty Acids UnsaturatedFemaleInsulin ResistancedietBody mass indexJournal of lipid research
researchProduct

Impact of physical exercise on sensor performance of the FreeStyle Libre intermittently viewed continuous glucose monitoring system in people with Ty…

2019

AIMS To evaluate the sensor performance of the FreeStyle Libre intermittently viewed continuous glucose monitoring system using reference blood glucose levels during moderate-intensity exercise while on either full or reduced basal insulin dose in people with Type 1 diabetes. METHODS Ten participants with Type 1 diabetes [four women, mean ± sd age 31.4 ± 9.0 years, BMI 25.5±3.8 kg/m2 , HbA1c 55±7 mmol/mol (7.2±0.6%)] exercised on a cycle ergometer for 55 min at a moderate intensity for 5 consecutive days at the clinical research facility, while receiving either their usual or a 75% basal insulin dose. After a 4-week washout period, participants performed the second exercise period having sw…

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismPhysical exerciseBiosensing Techniques03 medical and health sciencesYoung Adult0302 clinical medicineEndocrinologyInsulin Infusion SystemsInterquartile rangePredictive Value of TestsDiabetes mellitusInternal medicineInternal MedicinemedicineHumansInsulin030212 general & internal medicineExercise physiologyBlood Glucose MeasurementExerciseType 1 diabetesCross-Over StudiesDose-Response Relationship Drugbusiness.industryBlood Glucose Self-MonitoringEquipment Designmedicine.diseaseCrossover studyDiabetes Mellitus Type 1Equipment and SuppliesPredictive value of testsCardiologyFemalebusiness
researchProduct

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

2016

OBJECTIVE To compare the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in patients with type 2 diabetes not achieving adequate glycemic control on metformin alone. RESEARCH DESIGN AND METHODS In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin. Liraglutide was administered once daily at any time of the day. Lixisenatide was administered once daily within 1 h prior to the morning or evening meal. RESULTS At week 26, liraglutide reduced HbA1c (primary end point) more than lixisenatide (estimated treatment difference −0.62% [95% CI −0.8; −0.4]; P &amp;…

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyHypoglycemiaDrug Administration Schedulelaw.inventionYoung Adult03 medical and health sciencesLixisenatidechemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicineInternal MedicinemedicineClinical endpointHumansHypoglycemic AgentsAgedGlycemicAged 80 and overGlycated HemoglobinAdvanced and Specialized NursingLiraglutidebusiness.industryBody WeightLiraglutideMiddle AgedPostprandial Periodmedicine.diseaseHypoglycemiaMetforminMetforminTreatment OutcomeEndocrinologyDiabetes Mellitus Type 2chemistryDrug Therapy CombinationFemalePeptidesbusinessmedicine.drugDiabetes Care
researchProduct

Circulating Apelin is increased in patients with type 1 or type 2 diabetes and is associated with better glycaemic control

2013

SummaryContext Apelin is an adipokine expressed in several tissues and it appears to be involved in energy metabolism. Objective The aim of this study was to determine serum apelin levels in a large cohort of patients with type 1 and type 2 diabetes and control subjects and to correlate the results with glycaemic control. Design and Participants One hundred and thirty patients with type 1 diabetes, 98 patients with type 2 diabetes and 162 controls were enrolled in the study. Apelin levels were measured by enzyme-linked immunosorbent assay. Results Serum apelin levels were significantly higher in type 1 and type 2 diabetic patients than in controls (P < 0·0001). Serum apelin levels were high…

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismAdipokineType 2 diabetesEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusmedicineHumansAgedGlycated HemoglobinType 1 diabetesbusiness.industryCase-control studyMiddle Agedmedicine.diseaseObesityUp-RegulationApelinDiabetes Mellitus Type 1EndocrinologyDiabetes Mellitus Type 2Case-Control StudiesApelinIntercellular Signaling Peptides and ProteinsFemaleInsulin ResistancebusinessBiomarkersClinical Endocrinology
researchProduct